What is Landos Biopharma, Inc. (LABP) stock price today?

Landos Biopharma, Inc. (LABP) is currently trading at $22.93, up 0.57% today.

What is LABP P/E ratio?

Landos Biopharma, Inc.'s P/E ratio is -6.55. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is LABP return on equity (ROE)?

Landos Biopharma, Inc.'s return on equity (ROE) is -61.86%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Landos Biopharma, Inc.'s market cap?

Landos Biopharma, Inc. has a market capitalization of $71.68M.

NASDAQ · Biotechnology

Landos Biopharma, Inc. (LABP) Stock

$22.93 +0.57% NASDAQ: LABP Healthcare

Valuation

Metric	Value
Price	$22.93
Market Cap	$71.68M
P/E Ratio	-6.55
P/B Ratio	4.53
P/S Ratio	0.00
EPS (TTM)	$-3.50
52-Week High	$22.94
52-Week Low	$3.15
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-61.86%
ROA	-57.66%
ROCE	-71.49%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	6.09

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$0	$0	$18.0M	$0	$0
Operating Profit	$-13.0M	$-31.0M	$-39.0M	$-41.0M	$-23.0M
Net Profit	$-14.0M	$-30.0M	$-38.0M	$-38.0M	$-22.0M
EPS	$-3.47	$-7.51	$-9.50	$-9.44	$-3.50
Op Margin	—	—	-215.6%	—	—

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$50.0M	$30.0M	$93.0M	$45.0M	$38.0M
Total Liabilities	$76.0M	$84.0M	$17.0M	$6.0M	$6.0M
Cash	$10.0M	$2.0M	$8.0M	$37.0M	$38.0M
Borrowings	$0	$0	$0	$0	$0

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-10.0M	$-23.0M	$-27.0M	$-46.0M	$-20.0M
Investing Cash Flow	$-40.0M	$14.0M	$-59.0M	$74.0M	$8.0M
Financing Cash Flow	$60.0M	$2.0M	$92.0M	$0	$11.0M
Net Cash Flow	$9.0M	$-7.0M	$6.0M	$28.0M	$1.0M
Free Cash Flow	$-10.0M	$-23.0M	$-28.0M	$-46.0M	$-20.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.18
EV / EBITDA	-1.50
FCF Yield	-28.57%
Quick Ratio	6.09
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHLAchilles Therapeutics plc	$1.48	+0.68%	-0.85	$60.83M	0.00%
BLIBerkeley Lights, Inc.	$1.20	-5.88%	-0.85	$86.61M	0.00%
HTBXHeat Biologics, Inc.	$2.38	+0.42%	-1.87	$61.07M	0.00%
IGMSIGM Biosciences, Inc.	$1.27	+0.00%	1.75	$77.50M	0.00%
JBIO	$21.96	-1.26%	-6.16	$716.46M	0.00%

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is a biopharmaceutical firm operating in the clinical stage, focused on the discovery and development of innovative oral therapies aimed at treating a range of autoimmune disorders. Their leading clinical-stage candidate, omilancor, is an oral, gut-specific therapeutic designed to modulate lanthionine synthetase C-like protein 2 (LANCL2) activity. It is currently being investigated for treating ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis. Another pipeline asset, NX-13, is also an oral therapeutic localized to the gut, targeting the NOD-like receptor X1 (NLRX1) pathway, a mitochondrial receptor involved in regulating inflammatory cytokine production, for UC and CD. Furthermore, LABP-104 is an oral, small-molecule LANCL2 agonist designed to be systemically bioavailable, with potential applications in systemic lupus erythematosus and rheumatoid arthritis (RA). Beyond these clinical programs, Landos maintains a robust preclinical pipeline, featuring several promising compounds: LABP-66, an oral small molecule, acts as a NOD-like pathway agonist and is being explored for multiple sclerosis and Alzheimer's disease. LABP-69 is an oral PLXDC2 agonist targeting diabetic nephropathy and RA. LABP-73, another oral small molecule, modulates the NLRX1 pathway for potential use in asthma and chronic obstructive pulmonary disease. And LABP-111, an oral small molecule LANCL2 pathway agonist, is under investigation for nonalcoholic steatohepatitis and type 1 diabetes. Established in 2017, the company's corporate headquarters are situated in Blacksburg, Virginia.

Landos Biopharma, Inc. is headquartered in US.

Landos Biopharma, Inc. (LABP) stock trades at $22.93 with a market capitalization of $71.68M. The stock is valued at a price-to-earnings (P/E) ratio of -6.55, price-to-book of 4.53, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.15 and $22.94, and currently trades at its 52-week high.

On profitability, Landos Biopharma, Inc. generates a return on equity (ROE) of -61.86%, return on capital employed of -71.49%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: landosbiopharma.com